AURORA, ON, Jul 25, 2011 (MARKETWIRE via COMTEX) — Helix BioPharma Corp. CA:HBP +0.78% HBP -0.74% (frankfurt:HBP), a developer of biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced that it has received approval from the Central Register of Clinical Trials at the Polish Ministry of Health of its European clinical trial application (“CTA”) to perform the Company’s planned Phase I/II clinical safety, tolerability and preliminary efficacy study of its lung cancer drug candidate, L-DOS47.

L-DOS47 is Helix’s first drug candidate under development based upon the Company’s novel DOS47 technology, which is designed to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction. L-DOS47 is an immunoconjugate-based drug candidate intended to offer an innovative approach to the first-line treatment of inoperable, locally advanced, recurrent or metastatic, non-small cell lung cancer (“NSCLC”).